EpiCept Corporation Completes Merger With Maxim Pharmaceuticals, Inc.

Published: Jan 05, 2006

ENGLEWOOD CLIFFS, N.J.--(BUSINESS WIRE)--Jan. 4, 2006--EpiCept Corporation (Nasdaq: EPCT): Transaction Highlights: Creates a balanced portfolio of late-stage to early-stage product candidates for the treatment of pain and cancer. The combined portfolio includes one product candidate targeted for 2006 registration in Europe, three products in advanced development, three products in Phase II, one in Phase I and one expected to enter Phase I in 2006.

Back to news